Antibody therapeutics for epithelial ovarian cancer

Mason Ruiz, Ningyan Zhang, Anil K. Sood, Zhiqiang An

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Introduction: High-grade serous ovarian carcinoma (HGSC) is an aggressive subtype of epithelial ovarian carcinoma (EOC) and remains the most lethal gynecologic cancer. A lack of effective and tolerable therapeutic options and nonspecific symptoms at presentation with advanced stage of disease are among the challenges in the management of the disease. Areas covered: An overview of ovarian cancer, followed by a discussion of the current therapeutic regimes and challenges that arise during and after the treatment of EOC. We discuss different formats of antibody therapeutics and their usage in targeting validated targets implicated in ovarian cancer, as well as three emerging novel proteins as examples recently implicated in their contribution to adaptive resistance in ovarian cancer. Expert opinion: Antibody therapeutics allow for a unique and effective way to target proteins implicated in cancer and other diseases, and have the potential to radically change the outcomes of patients suffering from ovarian cancer. The vast array of targets that have been implicated in ovarian cancer and yet the lack of effective therapeutic options for patients further stresses the importance of discovering novel proteins that can be targeted, as well as predictive biomarkers that can inform the stratification of patients into treatment-specific populations.

Original languageEnglish (US)
Pages (from-to)1379-1391
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume22
Issue number11
DOIs
StatePublished - 2022

Keywords

  • Adaptive resistance
  • angiogenesis
  • antibody therapy
  • CD5L
  • EGFL6
  • epithelial ovarian cancer
  • hypoxia
  • MSMP
  • ovarian cancer

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Antibody therapeutics for epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this